Quentis Therapeutics is a preclinical stage biotechnology company that is translating novel biology into new therapeutic approaches to help more cancer patients benefit from immunotherapy.
Jecure is focused on the discovery of novel therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) and liver fibrosis. Jecure’s scientific founder is Dr. Ariel Feldstein, Division Chief of Gastroenterology at UCSD School of Medicine and a leading physician scientist in hepatology. With operations in the biotech hub of San Diego, California, Jecure combines emerging NASH biology from Dr. Feldstein’s lab, a proprietary liver disease platform, and an elite discovery team of veteran pharma/biotech scientists. Jecure’s lead program has identified small molecule inhibitors of the NLRP3 inflammasome, a novel target and pro-inflammatory driver of NASH. Jecure is backed by top-tier life science investor Versant Ventures.
Pandion Therapeutics is a biotechnology company developing bispecific antibody therapeutics to achieve localized immunomodulation at the site of disease for durable, tissue-specific treatment, while avoiding the systemic immunosuppression of conventional medicines.
Jnana is committed to discovering and developing medicines that will make a transformative difference for patients using the first drug discovery platform dedicated to targeting the solute carrier (SLC) family of transporters.
Nouscom is developing next-generation immunotherapies to beat cancer.
Crinetics Pharmaceuticals explores the inner life of GPCRs to discover and develop novel therapeutics targeting peptide hormone receptors for the treatment of rare endocrine disorders and endocrine-related cancers.
VenatoRx is a developing next-generation antibiotics to treat multi-drug resistant (MDR) infections.
Vividion is a biotechnology company focused on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome-wide drug and target discovery.
Repare is developing new, precision oncology drugs for patients that target specific vulnerabilities of tumor cells.
Northern Biologics is developing novel therapeutic antibodies for the treatment of human diseases in oncology, fibrosis, and other diseases.
PIQUR is a Swiss pharmaceutical company focusing on the discovery and development of innovative small molecule therapeutics based on lipid kinase (PI3K) and mTOR inhibition for the treatment of cancer as well as other indications.
Anokion is focused on leveraging its proprietary immune tolerance technology to develop novel protein therapeutics and treatments for autoimmune diseases.
Mosaic Biomedicals is a Barcelona-based company that develops personalized cancer treatments with a dual mechanism of action to eliminate cancer stem cells and reactivate the tumor’s immune system. Mosaic’s innovative treatments are derived from a deep understanding of the tumor biology and aim to offer safer and more effective options to cancer patients.
Inception IBD is focused on translating academic discoveries in the field of IBD into first-in-class small molecule drugs.
Inception 3 is focused on the discovery of therapeutics for sensorineural hearing loss. The company has entered into a partnership with Roche with a pre-negotiated acquisition at IND.
VLST Corp. has developed a novel and streamlined approach to speed the development of effective therapeutics for the treatment of inflammatory and autoimmune diseases.
Theraclone Sciences, Inc. is focused on developing novel human therapeutic antibodies for the treatment of infectious diseases.
Acumen is revolutionizing the diagnosis and treatment of autism and other disorders through smartphone-enabled digital behavior evaluation, improving outcomes for patients and simplifying care for specialists.
PhaseRx is developing a novel approach to intracellular delivery of macromolecules.
Inception 2 is focused on Oncology. The company is translating biological insights into novel, first-in-class small molecule drugs for CLL and other oncology indications spanning both liquid and solid tumors.
Inception 1 is translating biological insights into novel, first-in-class, small molecule drugs to treat diseases of aging.
Bird Rock is a drug discovery and development company focused on first-in-class antibodies targeting G protein coupled receptors (GPCRs).